Company Overview and News

 
Parkway Minerals intersects potassium-rich greensands at Dambadgee

2018-08-21 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) has hit thick, potassium-rich greensands in aircore drilling at its Dandaragan Fertiliser Project in Western Australia.
PWN

 
Parkway Minerals reviews potash project after completing drilling program

2018-08-08 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) is reviewing its Lake Barlee Potash Project in Western Australia after completing a proof of concept drill program.
PWN

1
Parkway Minerals raises $500,000 to support fertiliser feedstock project

2018-06-25 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) has raised $500,000 via a private placement of about 50 million shares at 1 cent each.
PWN

1
Parkway Minerals to boost cash position for fertiliser feedstock projects

2018-06-19 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) continues to advance its exploration projects in Western Australia, focused on sulphate of potash and glauconite deposits.
PWN

1
Parkway Minerals looking to partner at Dandaragan Trough as it develops Lake Barlee

2018-06-18 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) managing director Patrick McManus speaks with Proactive Investors about the company's two fertiliser projects in Western Australia, and its proprietary K-Max® potassium extraction process.
PWN

1
Parkway Minerals to commence drilling for potash at salt lake

2018-06-06 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) will commence initial proof-of-concept drilling next week at its 100% owned Lake Barlee Potash project in Western Australia.
PWN ASL

1
Parkway Minerals granted US patent for its potassium extraction process

2018-05-31 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) has been granted a US Patent for its K-Max® potassium extraction process.
PWN

1
Parkway Minerals benefits from increasing demand and prices for fertilisers

2018-04-19 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) managing director Patrick McManus explains the company's approach to meeting demand for fertiliser feedstocks, phosphate and potash, which is growing exponentially in line with global population growth.
PWN

1
Parkway Minerals' shares up on back of increase in Davenport Resources' potash resource

2018-04-17 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) is a beneficiary of Davenport Resources Ltd’s (ASX:DAV) increase in its potash resource at the Mühlhausen-Nohra Mining Licence in Germany.
PWN

1
Parkway Minerals' stake in Davenport Resources increases to 34.3% after meeting potash milestone

2018-04-04 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) has had 17.9 million shares in Davenport Resources Ltd (ASX:DAV) converted, taking its total holding to 37.1 million shares.
PWN

1
Parkway Minerals gets boost from Davenport’s maiden potash resource

2018-04-03 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) has a 26% stake in Davenport Resources (ASX:DAV) which has today posted its maiden JORC resource.
PWN

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:PWN / POTASH WEST NL on message board site Silicon Investor.

epwn epwn epwn Banking and Finance? How about a pawn shop? - PWN Banking and Finance? How about a pawn shop? - PWN Banking and Finance? How about a pawn shop? - PWN